Astellas Pharma : Medivation and Astellas Announce Enzalutamide (Formerly MDV3100) Data to Be Presented at ASCO Annual Meeting 2012 (pdf 47KB)
05/20/2012| 09:21pm US/Eastern
Recommend:
Patrick Machado Jenny Kite
Chief Business & Financial Officer Corporate
Communications
(415) 829-4101 (847) 317-5405
Anne Bowdidge Mike Beyer
Senior Director, Investor Relations Sam Brown, Inc (media for
both companies) (650) 218-6900 (773) 463-4211
Medivation and Astellas Announce Enzalutamide (Formerly
MDV3100) Data to Be
Presented at ASCO Annual Meeting 2012
SAN FRANCISCO, CA AND TOKYO - May 18, 2012 -- Medivation Inc.
(NASDAQ: MDVN) and Astellas Pharma Inc. today announced that
six abstracts related to enzalutamide (formerly MDV3100) will
be presented at the upcoming American Society of Clinical
Oncology (ASCO) Annual Meeting in Chicago, IL from June 1 -5,
2012.
Details of the abstracts are as follows:
(Abstract #4519): Primary, secondary, and quality-of-life
endpoint results from the phase III AFFIRM study of MDV3100,
an androgen receptor signaling inhibitor
• Saturday, June 2 from 8:30 a.m. - 8:45 a.m.
Presenter: Johann S. De Bono, MB, ChB, FRCP, MSc, PhD
Clinical Science Symposium: New Paradigms for Hormone Therapy
in Prostate Cancer
Location: E Arie Crown Theater
(Abstract #564 / Poster #4G): Effect of MDV3100,
an androgen receptor signaling inhibitor, on tumor growth of
estrogen and androgen receptor-positive (ER+/AR+) breast
cancer xenografts
• Saturday, June 2 from 8:00 a.m. to noon
Author: Anthony D. Elias, MD
General Poster Session: Breast Cancer
Location: S Hall A2
(Abstract #TPS668 / Poster #18B): MDV3100-08: A phase I
open-label, dose-escalation study evaluating the safety,
tolerability, and pharmacokinetics of MDV3100 in women with
incurable breast cancer
• Saturday, June 2 from 8:00 a.m. to noon
Author: Anthony D. Elias, MD
General Poster Session: Breast Cancer
Location: S Hall A2
(Abstract #TPS4695 / Poster #16F): A randomized, open-label,
phase II study of MDV3100 alone or in combination with
leuprolide and dutasteride as neoadjuvant therapy to
prostatectomy in intermediate and high-risk prostate cancer
• Sunday, June 3 from 8:00 a.m. to noon
Author: Robert B. Montgomery, MD
General Poster Session: Genitourinary Cancer
Location: S Hall A2
(Abstract #TPS4698 / Poster #17A): TERRAIN: A randomized,
double-blind, phase II study comparing MDV3100 with
bicalutamide (Bic) in men with metastatic castrate-resistant
prostate cancer (CRPC)
• Sunday, June 3 from 8:00 a.m. to noon
Author: Edwina S. Baskin-Bey, MD
General Poster Session: Genitourinary Cancer
Location: S Hall A2
(Abstract #3072 / Poster #16F): Effect of MDV3100, a novel
androgen receptor signaling inhibitor, on cell proliferation
and tumor size in an apocrine breast cancer xenograft model
• Monday, June 4 from 8:00 A a.m. - noon
Author: Sebastián Bernales, PhD
General Poster Session: Developmental Therapeutics
Location: S Hall A2
About Medivation
Medivation, Inc. is a biopharmaceutical company focused on
the rapid development of novel small molecule drugs to treat
serious diseases for which there are limited treatment
options. Medivation aims to transform the treatment of these
diseases and offer hope to critically ill patients and their
caregivers. Together with its corporate partner Astellas,
Medivation currently has the investigational drug
enzalutamide in Phase 3 development to treat advanced
prostate cancer and in Phase 1 development to treat breast
cancer. For more information, please visit us at
www.medivation.com.
About Astellas Pharma Inc.
Astellas Pharma Inc. is a pharmaceutical company dedicated to
improving the health of people around the world through
provision of innovative and reliable pharmaceuticals. The
organization is committed to becoming a global category
leader in Oncology, and has several oncology compounds in
development in addition to MDV3100. For more information on
Astellas Pharma Inc., please visit our website at www.astellas.com/en.
distributed by
|
|
Recommend :
